🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
www.nephjc.com/news/2026/9/...
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
www.nephjc.com/news/2026/9/...
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
Gracias @danyrcal.bsky.social y @dramiliflores.bsky.social
www.nephjc.com/news/target2
Gracias @danyrcal.bsky.social y @dramiliflores.bsky.social
www.nephjc.com/news/target2
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
Does donor quality change the equation?👀
Check out this week's #NephJC summary! #NephSky
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
📅 Nov 5: Discover the first results of the Prepare for Kidney Care trial in an ISN webinar.
🔗 Register: https://bit.ly/4hykcWw
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
www.nephjc.com/news/tolvapt...
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
www.nephjc.com/news/tolvapt...
#Nephpearls #AKIinICU #NephJC #NephSky
👉 shop.lww.com/Handbook-of-...
#Nephpearls #AKIinICU #NephJC #NephSky
👉 shop.lww.com/Handbook-of-...
www.nephjc.com/news/potassi...
www.nephjc.com/news/potassi...
www.bmj.com/content/394/...
Join us www.nephjc.com/
www.bmj.com/content/394/...
Join us www.nephjc.com/
🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵
www.sciencedirect.com/science/arti...
🫘💊 START your steroids! A question we ask constantly but adult RCT data rarely answers after remission in steroid-sensitive MCD/FSGS, how long should the prednisolone taper actually be? 🧵
www.sciencedirect.com/science/arti...
Starting is easy, but stopping can be challenging.
Are longer courses of steroids better for longer remissions? How quickly do you taper? 🐇🐢
#NephSky #NephJC
www.nephjc.com/news/startsteroidtaper
Checkout the VA by @divyaveerssneph.bsky.social
This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS).
💊Steroids: easy to start🟢 but hard to stop 🛑.
#NephSky
www.nephjc.com/news/starttrial
Checkout the VA by @divyaveerssneph.bsky.social
This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS).
💊Steroids: easy to start🟢 but hard to stop 🛑.
#NephSky
www.nephjc.com/news/starttrial
#NephSky #NephJC
¿Cuánto debe durar la reducción gradual de esteroides tras la remisión de una podocitopatía?
www.nephjc.com/news/startspanish
#NephSky #NephJC
¿Cuánto debe durar la reducción gradual de esteroides tras la remisión de una podocitopatía?
www.nephjc.com/news/startspanish
Starting is easy, but stopping can be challenging.
Are longer courses of steroids better for longer remissions? How quickly do you taper? 🐇🐢
#NephSky #NephJC
www.nephjc.com/news/startsteroidtaper
Starting is easy, but stopping can be challenging.
Are longer courses of steroids better for longer remissions? How quickly do you taper? 🐇🐢
#NephSky #NephJC
www.nephjc.com/news/startsteroidtaper
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd
Checkout the VA by @divyaveerssneph.bsky.social
This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS).
💊Steroids: easy to start🟢 but hard to stop 🛑.
#NephSky
www.nephjc.com/news/starttrial
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
Enjoy reading! 👇🏻 #START trial #NephJC #NephSky
Starting is easy, but stopping can be challenging.
Are longer courses of steroids better for longer remissions? How quickly do you taper? 🐇🐢
#NephSky #NephJC
www.nephjc.com/news/startsteroidtaper
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
nephjc.com/news/startst...
www.nephjc.com/news/starttr...
www.nephjc.com/news/startsp...
Andreea Manolea,
Farah Wehbe,
David White
nephjc.com/news/startst...
www.nephjc.com/news/starttr...
www.nephjc.com/news/startsp...
Andreea Manolea,
Farah Wehbe,
David White
www.kidneymedicinejournal.org/article/S259... in @kidneymed.bsky.social
www.kidneymedicinejournal.org/article/S259... in @kidneymed.bsky.social